Genetic and chemical activation of TFEB mediates clearance of aggregated α-synuclein

PloS One
Kiri KilpatrickLaura Segatori

Abstract

Aggregation of α-synuclein (α-syn) is associated with the development of a number of neurodegenerative diseases, including Parkinson's disease (PD). The formation of α-syn aggregates results from aberrant accumulation of misfolded α-syn and insufficient or impaired activity of the two main intracellular protein degradation systems, namely the ubiquitin-proteasome system and the autophagy-lysosomal pathway. In this study, we investigated the role of transcription factor EB (TFEB), a master regulator of the autophagy-lysosomal pathway, in preventing the accumulation of α-syn aggregates in human neuroglioma cells. We found that TFEB overexpression reduces the accumulation of aggregated α-syn by inducing autophagic clearance of α-syn. Furthermore, we showed that pharmacological activation of TFEB using 2-hydroxypropyl-β-cyclodextrin promotes autophagic clearance of aggregated α-syn. In summary, our findings demonstrate that TFEB modulates autophagic clearance of α-syn and suggest that pharmacological activation of TFEB is a promising strategy to enhance the degradation of α-syn aggregates.

References

Jul 21, 1995·The Journal of Biological Chemistry·E P KilsdonkG H Rothblat
Nov 1, 1996·Journal of Pharmaceutical Sciences·R A Rajewski, V J Stella
Aug 28, 1997·Nature·M G SpillantiniM Goedert
Apr 12, 2000·Biochemistry·M P HaynesG H Rothblat
May 30, 2001·Current Opinion in Genetics & Development·M Goedert
Jul 4, 2001·Nature Reviews. Neuroscience·M Goedert
Aug 3, 2001·Nature Reviews. Neuroscience·K S McNaughtP Jenner
Jan 11, 2003·American Journal of Medical Genetics. Part a·Judit VárkonyiEllen Sidransky
Apr 30, 2003·The Journal of Biological Chemistry·Julie L WebbDavid C Rubinsztein
Sep 16, 2003·Neuron·William Dauer, Serge Przedborski
Apr 15, 2004·The Journal of Pharmacology and Experimental Therapeutics·V MonnaertE Monflier
Apr 22, 2004·Journal of Neuropathology and Experimental Neurology·Yuko SaitoShigeo Murayama
Jul 24, 2004·Nature Medicine·Edward H Koo, Raphael Kopan
Jul 30, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Doris L FortinRobert H Edwards
Dec 2, 2004·Nature Reviews. Drug Discovery·Mark E Davis, Marcus E Brewster
Sep 30, 2005·The Journal of Biological Chemistry·Atsushi IwataRon R Kopito
Dec 2, 2005·Nature·Frederick R Maxfield, Ira Tabas
Feb 9, 2006·Bioorganic & Medicinal Chemistry Letters·Sébastien TilloyEric Monflier
Jul 29, 2006·Autophagy·Ana Maria CuervoAlexei Terman
Oct 24, 2006·Biochemical and Biophysical Research Communications·Jinglei ChengToyoshi Fujimoto
Jan 4, 2008·The Journal of Clinical Investigation·Marta Martinez-VicenteAna Maria Cuervo
Oct 16, 2008·Current Protein & Peptide Science·Vladimir N Uversky
Oct 22, 2008·Biochimica Et Biophysica Acta·Natalia B NedelskyJ Paul Taylor
Jun 27, 2009·Science·Marco SardielloAndrea Ballabio
Oct 30, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Brian SpencerEliezer Masliah
Feb 11, 2010·Cell·Noboru MizushimaBeth Levine
Mar 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Anton I RosenbaumFrederick R Maxfield
May 22, 2010·Molecular Microbiology·Tomotake Kanki, Daniel J Klionsky
Sep 17, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Benjamin DehayMiquel Vila
Sep 22, 2010·The Journal of Cell Biology·Ashley R WinslowDavid C Rubinsztein
Nov 12, 2010·Cold Spring Harbor Perspectives in Biology·Esther Wong, Ana Maria Cuervo
Dec 3, 2010·PloS One·Fannie W ChenYiannis A Ioannou
May 28, 2011·Science·Carmine SettembreAndrea Ballabio
Oct 14, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Darius Ebrahimi-FakhariVivek K Unni
Nov 15, 2011·Cell·Noboru Mizushima, Masaaki Komatsu

❮ Previous
Next ❯

Citations

Jan 28, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Maria XilouriLeonidas Stefanis
Mar 2, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Benjamin DehayErwan Bezard
Sep 5, 2015·Current Opinion in Biotechnology·Lauren Popp, Laura Segatori
Mar 13, 2016·Trends in Neurosciences·Heidi Martini-StoicaHui Zheng
Dec 22, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Caroline CoisneFabien Gosselet
Apr 4, 2017·Cell Chemical Biology·Yuxi ZhangDaniel Hesselson
Jan 27, 2017·Molecular Neurodegeneration·Tim E MoorsWilma D J van de Berg
Jul 14, 2017·Brain Pathology·Fang GuoWeidong Le
Jun 3, 2016·Journal of Cell Science·Gennaro Napolitano, Andrea Ballabio
May 29, 2018·Journal of Neurochemistry·Matteo AudanoNico Mitro
Aug 18, 2018·Nature Reviews. Drug Discovery·Barry BolandMark J Millan
Feb 28, 2018·Current Medicinal Chemistry·Silvia Cerri, Fabio Blandini
Sep 15, 2019·Disease Models & Mechanisms·Robert A BrownOla Awad
Nov 30, 2019·Drug Development Research·Eran Schmukler, Ronit Pinkas-Kramarski
Nov 16, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Giovanni BellomoLucilla Parnetti
Mar 7, 2020·Biomolecules·Margaux TeilBenjamin Dehay
Oct 13, 2017·Frontiers in Molecular Neuroscience·Destiny-Love ManeckaThomas M Durcan
Jun 4, 2018·Brain : a Journal of Neurology·Andrés D Klein, Joseph R Mazzulli
Apr 20, 2016·Annual Review of Neuroscience·Alessandro FraldiCarmine Settembre
Oct 17, 2016·Essays in Biochemistry·Matthew P Jackson, Eric W Hewitt
Aug 19, 2018·Nature Communications·Gennaro NapolitanoAndrea Ballabio
Feb 13, 2019·International Journal of Molecular Sciences·Michiel Van BulckJose A Morales-Garcia
Jun 12, 2019·Cells·Marie-Laure ArotcarenaBenjamin Dehay
Mar 21, 2019·International Journal of Molecular Sciences·Alessandro MaginiBrunella Tancini
Jul 18, 2019·Frontiers in Cell and Developmental Biology·Chiara Di MaltaCarmine Settembre
Oct 1, 2016·Journal of Huntington's Disease·Petr VodickaMarian DiFiglia
Jan 27, 2019·Scientific Reports·Sijie TanEsther Wong
May 28, 2019·Frontiers in Neuroscience·Šárka LehtonenJari Koistinaho
Oct 3, 2020·Pharmaceuticals·Adrián MatencioFrancesco Trotta
Dec 2, 2020·Fundamental & Clinical Pharmacology·Anaelle da CostaMathieu Charvériat
Jan 10, 2021·Scientific Reports·M J Vijay KumarJames P Clement
Oct 26, 2020·Drug Discovery Today·Ju-Xian SongMin Li
Nov 11, 2019·Neurobiology of Disease·Zahra AfghahJonathan D Geiger
Nov 24, 2020·Oxidative Medicine and Cellular Longevity·Natalia Jimenez-Moreno, Jon D Lane

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
Fluorescence microscopy
flow cytometry
confocal microscopy
nuclear translocation
Fluorescence
transfection
PCR
gel filtration

Software Mentioned

NIH ImageJ
CLEAR
Colocalization Colormap script
ImageJ
CFX Manager

Related Concepts

Related Feeds

Parkinson's Disease & Autophagy

Autophagy leads to degradation of damaged proteins and organelles by the lysosome. Impaired autophagy has been implicated in several diseases. Here is the role of autophagy in Parkinson’s disease.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Autophagy & Disease

Autophagy is an important cellular process for normal physiology and both elevated and decreased levels of autophagy are associated with disease. Here is the latest research.

Autophagy Networks

Autophagy is a lysosomal pathway that involves degradation of proteins and functions in normal growth and pathological conditions, through a series of complex networks. The catabolic process involves delivery of proteins and organelles to the lysosome. Here is the latest research on autophagy networks.

Parkinson's Disease & Autophagy (MDS)

Autophagy leads to degradation of damaged proteins and organelles by the lysosome. Impaired autophagy has been implicated in several diseases. Here is the role of autophagy in Parkinson’s disease.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alpha-Synuclein Aggregation

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.